Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IKNA | US
-0.01
-0.58%
Healthcare
Biotechnology
30/06/2024
17/10/2024
1.71
1.71
1.74
1.68
Ikena Oncology Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930 a paralog selective inhibitor of the transcriptional enhanced associate domain a transcription factor in the Hippo signaling pathway. It also develops IK-595 designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175 a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors including urothelial carcinomas. Ikena Oncology Inc. was incorporated in 2016 and is headquartered in Boston Massachusetts.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
9.9%1 month
18.8%3 months
27.2%6 months
52.1%-
-
0.58
0.06
0.06
-0.54
0.93
-
-71.34M
82.52M
82.52M
-
-3.92K
-
-87.90
-44.54
5.01
0.54
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.11
Range1M
0.11
Range3M
0.27
Rel. volume
0.68
Price X volume
44.55K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
CytomX Therapeutics Inc | CTMX | Biotechnology | 1.16 | 90.62M | -1.69% | 7.67 | -37.61% |
Werewolf Therapeutics Inc. Common Stock | HOWL | Biotechnology | 2.05 | 89.59M | -0.49% | n/a | 35.26% |
BioAtla Inc. | BCAB | Biotechnology | 1.85 | 89.42M | -5.61% | n/a | 5.30% |
Leap Therapeutics Inc | LPTX | Biotechnology | 2.33 | 89.16M | -2.92% | n/a | 0.73% |
MediciNova Inc | MNOV | Biotechnology | 1.805 | 88.53M | -2.43% | n/a | 0.86% |
Clearside Biomedical Inc | CLSD | Biotechnology | 1.15 | 85.96M | 2.68% | n/a | -168.27% |
CASI Pharmaceuticals Inc | CASI | Biotechnology | 5.43 | 83.95M | 0.56% | n/a | 167.26% |
PMV Pharmaceuticals Inc | PMVP | Biotechnology | 1.6 | 83.54M | 0.00% | n/a | 6.06% |
Aclaris Therapeutics Inc | ACRS | Biotechnology | 1.17 | 83.47M | 0.86% | n/a | 2.10% |
Ovid Therapeutics Inc | OVID | Biotechnology | 1.17 | 83.04M | -0.85% | n/a | 18.40% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Saga Communications Inc | SGA | Broadcasting - Radio | 14.35 | 89.85M | 0.07% | 14.47 | 7.10% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.54 | 0.53 | Cheaper |
Ent. to Revenue | 0.93 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 0.58 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 27.16 | 72.92 | Lower Risk |
Debt to Equity | 0.06 | -1.24 | Expensive |
Debt to Assets | 0.06 | 0.25 | Cheaper |
Market Cap | 82.52M | 3.78B | Emerging |